Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology company focused on RAS-addicted cancers, announces participation in the Cowen 42nd Annual Health Care Conference. CEO Mark A. Goldsmith will engage in a fireside chat on March 7, 2022, at 11:10 a.m. Pacific. The virtual conference runs from March 7-9, 2022, with a live webcast available on the company’s website. A replay will be accessible for 14 days post-event. Revolution Medicines develops therapies targeting RAS proteins, including RMC-6236 and RMC-4630.

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42^nd Annual Health Care Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of the company’s participation are as follows:

• Cowen 42^nd Annual Health Care Conference
  Conference Date: March 7-9, 2022
  Fireside Chat Time/Date: 11:10 a.m. Pacific on Monday, March 7, 2022
  Format: Virtual conference; webcast available

To access the live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS^MULTI), RMC-6291(KRAS^G12C), RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

What is the date and time of Revolution Medicines' fireside chat at the Cowen 42nd Annual Health Care Conference?

Revolution Medicines' fireside chat is scheduled for March 7, 2022, at 11:10 a.m. Pacific.

How can I access the webcast of the Revolution Medicines fireside chat?

You can access the live webcast on the 'Events & Presentations' page of Revolution Medicines' website.

What are the dates of the Cowen 42nd Annual Health Care Conference?

The Cowen 42nd Annual Health Care Conference will take place from March 7-9, 2022.

What is the focus of Revolution Medicines' research and development?

Revolution Medicines focuses on developing novel targeted therapies for RAS-addicted cancers.

What are some of the products in Revolution Medicines' pipeline?

The pipeline includes RMC-6236, RMC-6291, RMC-9805, and RMC-4630, targeting various RAS proteins.